(PresseBox) (Munich , 07.05.2018) BayPAT, service provider offering services in the area of technology transfer, IP management and commercialization, today announced that its licensee Scintomics has signed a sub-license and option agreement with Blue Earth Diagnostics, Ltd. In July 2017, BayPAT has out-licensed the radiohybrid PSMA-targeted technology, developed at the Technical University of Munich (TUM) to Scintomics. As a licensor of Scintomics, BayPAT ab initiowas involved in the negotiations between Scintomics and Blue Earth Diagnostics offering support and solution-oriented approaches leading to fast and straightforward contract signing.
Under the terms of the agreement, Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of prostate specific membrane antigen (PSMA)-targeted radiohybrid agents for cancer imaging, together with an exclusive option to explore therapeutic applications. The out-licensed rhPSMA pharmaceuticals have potential in both imaging and therapy of prostate cancer. Blue Earth Diagnostics in close collaboration with Scintomics, TUM and BayPAT will drive development of a lead imaging compound, 18F-rhPSMA, and use joint forces to identify optimized therapeutic candidates for future development.
“We are very happy that BayPAT could support our licensee Scintomics to lay the foundation for rhPSMA to become a success story for prostate cancer patients by finding Blue Earth Diagnostics as an ideal partner for rapid commercialization of the rhPSMA radiopharmaceuticals.” Dr. Robert Phelps, BayPAT’s Chief Executive Officer said.
“We are very enthusiastic about the broad applicability of the versatile radiohybrid technology. It allows, for the very first time, the true bridging of functional imaging and radioligand therapy by labeling/activation of either the imaging or therapeutic option, without affecting a drug’s molecular structure,” said Saskia Kropf, Chief Executive Officer of Scintomics. In addition, Saskia Kropf is convinced “that this exciting agreement with Blue Earth Diagnostics on rhPSMAs will also pave the way for further rh-based targeted ligands for imaging and therapy.”
“This agreement supports our strategic focus and is the next step in advancing our mission to develop and deliver products that address unmet medical needs in prostate cancer,” said Jonathan Allis, D. Phil., CEO of Blue Earth Diagnostics.
rhPSMA was invented at the Technical University of Munich, Germany and commercialized by BayPAT. At the Technical University of Munich it has been utilized clinically in the diagnostic imaging of men with both primary and recurrent prostate cancer. 18F-rhPSMA consists of a prostate-specific membrane antigen (PSMA) receptor ligand, which attaches to and is internalized by prostate cancer cells, and is labeled with the 18F radioisotope for PET imaging. rhPSMA and other “rh” compounds, can also be labeled with the radioisotope 177Lu for therapeutic use.
Prostate cancer is the second leading cause of cancer-related death in men. While most primary prostate cancer can be successfully treated, the disease recurs in approximately one-third of patients. In some patients, recurrent disease is detectable only by a rise in prostate specific antigen (PSA) levels, yet the location of the recurrence cannot consistently be located by conventional imaging, potentially impacting subsequent management of these patients.
Scintomics GmbH was founded in 2006 and initially focused its business on the development and production of fully automated devices for GMP production of radiopharmaceuticals at hospitals and clinical sites. As part of Scintomics natural expansion in providing fully integrated radiopharmaceutical service, Scintomics has made itself a name worldwide as a highly specialized company for innovative and unique nuclear medicine tracer technology, both for imaging and therapy. On the road to continued expansion, Scintomics considers the radiohybrid tracer platform as an important milestone in its strategic position as one of the "global players" in the radiopharmaceutical business. Although the path through successful clinical studies is not an easy one, the rapid approval of the first radiohybrid, a rhPSMA tracer, will have highest priority for Scintomics.
The Bayerische Patentallianz GmbH (BayPAT) was founded in 2007 by the Universities of Bavaria e.V. and the Bavarian Universities of Applied Sciences e.V. as the central patent and marketing agency to foster technology transfer of Bavarian Universities, University Hospitals and Universities of Applied Sciences and is responsible for 33 research institutes. Under the umbrella of the Bavarian Research and Innovation Agency (BayFIA), BayPAT is a full-service technology management provider offering services in the area of technology transfer, IP management and commercialization. Key clients are the Bavarian Universities, University Hospitals and Universities of Applied Sciences and its over 25.000 associated scientists, as well as non-university research institutes, industry, and independent inventors worldwide. Main focus in assessing and exploiting IP are the areas of biotechnology, chemistry, medical engineering, physics, automotive industry, energy and environment engineering, information and communication technology as well as mechanical engineering.